438 related articles for article (PubMed ID: 31803974)
1. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T
EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974
[TBL] [Abstract][Full Text] [Related]
2. PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.
Wiede F; Ziegler A; Zehn D; Tiganis T
J Autoimmun; 2014 Sep; 53():105-14. PubMed ID: 24997008
[TBL] [Abstract][Full Text] [Related]
3. PTPN2 Deficiency Enhances Programmed T Cell Expansion and Survival Capacity of Activated T Cells.
Flosbach M; Oberle SG; Scherer S; Zecha J; von Hoesslin M; Wiede F; Chennupati V; Cullen JG; List M; Pauling JK; Baumbach J; Kuster B; Tiganis T; Zehn D
Cell Rep; 2020 Jul; 32(4):107957. PubMed ID: 32726622
[TBL] [Abstract][Full Text] [Related]
4. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
5. NR4A transcription factors limit CAR T cell function in solid tumours.
Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
[TBL] [Abstract][Full Text] [Related]
6. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
7. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
Wiede F; Shields BJ; Chew SH; Kyparissoudis K; van Vliet C; Galic S; Tremblay ML; Russell SM; Godfrey DI; Tiganis T
J Clin Invest; 2011 Dec; 121(12):4758-74. PubMed ID: 22080863
[TBL] [Abstract][Full Text] [Related]
8. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.
Wei J; Long L; Zheng W; Dhungana Y; Lim SA; Guy C; Wang Y; Wang YD; Qian C; Xu B; Kc A; Saravia J; Huang H; Yu J; Doench JG; Geiger TL; Chi H
Nature; 2019 Dec; 576(7787):471-476. PubMed ID: 31827283
[TBL] [Abstract][Full Text] [Related]
9. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
[TBL] [Abstract][Full Text] [Related]
10. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.
Fu W; Lei C; Liu S; Cui Y; Wang C; Qian K; Li T; Shen Y; Fan X; Lin F; Ding M; Pan M; Ye X; Yang Y; Hu S
Nat Commun; 2019 Sep; 10(1):4355. PubMed ID: 31554797
[TBL] [Abstract][Full Text] [Related]
11. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
12. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
Baumgartner CK; Ebrahimi-Nik H; Iracheta-Vellve A; Hamel KM; Olander KE; Davis TGR; McGuire KA; Halvorsen GT; Avila OI; Patel CH; Kim SY; Kammula AV; Muscato AJ; Halliwill K; Geda P; Klinge KL; Xiong Z; Duggan R; Mu L; Yeary MD; Patti JC; Balon TM; Mathew R; Backus C; Kennedy DE; Chen A; Longenecker K; Klahn JT; Hrusch CL; Krishnan N; Hutchins CW; Dunning JP; Bulic M; Tiwari P; Colvin KJ; Chuong CL; Kohnle IC; Rees MG; Boghossian A; Ronan M; Roth JA; Wu MJ; Suermondt JSMT; Knudsen NH; Cheruiyot CK; Sen DR; Griffin GK; Golub TR; El-Bardeesy N; Decker JH; Yang Y; Guffroy M; Fossey S; Trusk P; Sun IM; Liu Y; Qiu W; Sun Q; Paddock MN; Farney EP; Matulenko MA; Beauregard C; Frost JM; Yates KB; Kym PR; Manguso RT
Nature; 2023 Oct; 622(7984):850-862. PubMed ID: 37794185
[TBL] [Abstract][Full Text] [Related]
13. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
14. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
15. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
Riese MJ; Wang LC; Moon EK; Joshi RP; Ranganathan A; June CH; Koretzky GA; Albelda SM
Cancer Res; 2013 Jun; 73(12):3566-77. PubMed ID: 23576561
[TBL] [Abstract][Full Text] [Related]
16. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
[TBL] [Abstract][Full Text] [Related]
17. PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.
Wiede F; Sacirbegovic F; Leong YA; Yu D; Tiganis T
J Autoimmun; 2017 Jan; 76():85-100. PubMed ID: 27658548
[TBL] [Abstract][Full Text] [Related]
18. Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model.
Martin ML; Wall EM; Sandwith E; Girardin A; Milne K; Watson PH; Nelson BH
Breast Cancer Res Treat; 2010 Jun; 121(3):753-63. PubMed ID: 19789976
[TBL] [Abstract][Full Text] [Related]
19. Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.
Katkeviciute E; Hering L; Montalban-Arques A; Busenhart P; Schwarzfischer M; Manzini R; Conde J; Atrott K; Lang S; Rogler G; Naschberger E; Schellerer VS; Stürzl M; Rickenbacher A; Turina M; Weber A; Leibl S; Leventhal GE; Levesque M; Boyman O; Scharl M; Spalinger MR
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33001862
[TBL] [Abstract][Full Text] [Related]
20. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
